Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS SUMMARY: Franchise Brands blooms; Tlou Energy loss widens

Thu, 09th Mar 2023 14:32

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Franchise Brands PLC - Manchester-based owner of ChipsAway, Willow Pumps and Metro Rod brands - Pretax profit in 2022 jumps 78% to GBP10.3 million from GBP5.8 million in 2021, boosted by business to business division. Revenue grows 72% to GBP99.2 million from GBP57.7 million. Proposes final dividend of 1.1 pence per share, up from 0.9p a year ago. Total dividend is 2.0p per share, up 33% from 1.5p. Net cash as at December 31 grows to GBP8.0 million from GBP6.5 million. Executive Chair Stephen Hemsley says: "The excellent momentum in the B2B businesses has continued in 2023 to date, as we capture the defensive growth opportunities afforded by the group's mostly essential services, strong leadership positions in its chosen markets, and reputation for high quality, reliable services among its diversified client base. We look forward with confidence to expanding the business organically and by seeking further earnings-enhancing acquisitions."

----------

Hansard Global PLC - Isle of Man-based long-term savings provider - In six months to December 31, pretax profit grows to GBP3.1 million from GBP1.9 million a year prior. Maintains interim dividend of 1.8p per share. Net asset value per share as at December 31 falls to 15.6p from 16.7p a year ago. Anticipates sales of long-term savings products to continue to be impacted by global economic headwinds, but adds: "however, we are confident that our new product pipeline will lead to increased sales and long term growth in the business."

----------

N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - In 2022, pretax loss narrows to GBP1.2 million from GBP1.8 million in 2021. Research & development costs reduce to GBP577,525 from GBP1.2 million. Company does not make revenue in 2022 or 2021. Notes delays of research grade materials due to global shortages. Says work is underway, with full results expected by the end of the second quarter of 2023.

----------

Seraphim Space Investment Trust PLC - London-based space technology investment company - Net asset value per share as at December 31 declines 7.2% to 92.74 pence per share from 99.97p at June 30. Company does not expect to recommend payouts in the near future due to its focus on achieving capital growth. In its outlook, notes innovation of Western economies regarding the impact of Russia's war in Ukraine. Chair Will Whitehorn says: "The investment manager is actively engaged with numerous investment prospects, carefully selecting those with a strong growth premise and offer the highest returns for shareholders. It is taking a cautious approach to the allocation of cash between supporting existing portfolio companies, making new investments, and managing the company's working capital until the market improves and more capital can be raised."

----------

Tlou Energy Ltd - Brisbane, Australia-based power project developer with large gas field in Botswana - In the six months to December 31, pretax loss widens to AUD2.2 million from AUD1.3 million a year ago. Employee benefits expense increases to AUD564,644 from AUD320,901. Posts an interest expense of AUD296,013 compared to none a year ago. Expenses classified as other widen to AUD1.0m million from AUD585,650. Expects work on purpose-built operations facility for 10 megawatt development at Lesedi, Botswana to be completed during 2023, with potential annual generation of about USD10 million in revenue from the project.

----------

Town Centre Securities PLC - Leeds, England based property investment and car parking operator - Net asset value as at December 31 is virtually flat at 314 pence per share, compared to 313p a year ago. It is down 7.9% from 341p at June 30, 2022. Maintains interim dividend at 2.5p per share. EPRA net tangible assets per share as at June 30 falls to 306p from 333p a year ago. Looking ahead, says that trading performance seen in the first half of financial year 2023 is performing into the opening months of calendar year 2023, with rent collections robust at 99% of amounts invoiced at the last quarter now collected. "The momentum in our car parks recovery has continued through 2022 however for those car parks that are particularly reliant on office workers, this recovery remains slow," it adds.

----------

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Apr 2024 11:56

N4 Pharma strikes partnership deal for intracellular delivery

(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.

Read more
23 Apr 2024 13:32

IN BRIEF: N4 Pharma loss widens but "great optimism" remains

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."

Read more
18 Apr 2024 12:14

N4 Pharma sees potential in Nuvec delivery method for cancer treatment

(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.

Read more
15 Feb 2024 13:17

N4 Pharma shares jump on latest Nuvec developments

(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.

Read more
15 Feb 2024 12:06

IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
19 Jan 2024 13:00

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.

Read more
19 Jan 2024 09:26

IN BRIEF: N4 Pharma gets India patent for medical delivery system

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China.

Read more
16 Jan 2024 14:05

N4 Pharma subsidiary agrees work programme for glaucoma treatment

(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.

Read more
16 Jan 2024 13:26

IN BRIEF: N4 Pharma touts contract to test glaucoma treatment, ECP105

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London.

Read more
8 Jan 2024 12:30

N4 Pharma reports progress in Nuvec clinical research

(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

Read more
8 Jan 2024 09:11

N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8

(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.

Read more
18 Dec 2023 16:55

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

Read more
18 Dec 2023 12:43

N4 Pharma rises on successful results from Nuvec administration

(Alliance News) - N4 Pharma PLC on Monday announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Read more
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.